Table 1 Characteristics of 270 recruited NSCLC patients
Characteristics | Value |
|---|---|
Age, median(IQR) | 67.5 (60–75) |
Gender | |
 Female, N(%) | 158 (58.5) |
Smoking status | |
 Smoker, N(%) | 69 (25.6) |
ECOG PS score | |
 0, N(%) | 98 (36.3) |
 1, N(%) | 139 (51.5) |
 2, N(%) | 22 (8.1) |
  > 2, N(%) | 11 (4.1) |
Histology of NSCLC | |
 Adenocarcinoma, N(%) | 263 (97.4) |
 Squamous cell carcinoma, N(%) | 4 (1.5) |
 Others, N(%) | 3 (1.1) |
Clinical T stage | |
 1, N(%) | 35 (13.0) |
 2, N(%) | 78 (28.9) |
 3, N(%) | 44 (16.3) |
 4, N(%) | 106 (39.2) |
 Not available, N(%) | 7 (2.6) |
Clinical N stage | |
 0, N(%) | 69 (25.6) |
 1, N(%) | 20 (7.4) |
 2, N(%) | 75 (27.8) |
 3, N(%) | 104 (38.5) |
 Not available, N(%) | 2 (0.7) |
Clinical M stage | |
 0, N(%) | 10 (3.7) |
 1a, N(%) | 82 (30.4) |
 1b, N(%) | 41 (15.2) |
 1c, N(%) | 137 (50.7) |
Clinical stage | |
 Stage III, N(%) | 23 (8.5) |
 Stage IVA, N(%) | 110 (40.7) |
 Stage IVB, N(%) | 137 (50.8) |
EGFR mutation status | |
 Exon 19 deletion, N(%) | 117 (43.3) |
 Exon 21 L858R substitution, N(%) | 133 (49.3) |
 Others, N(%) | 20 (7.4) |
TKI | |
 Gefitinib, N(%) | 46 (17.0) |
 Erlotinib, N(%) | 85 (31.5) |
 Afatinib, N(%) | 139 (51.5) |
Adverse drug reaction to EGFR-TKI | |
 Yes, N(%) | 130 (48.1) |
Progression free survival, median(months) | 11.5 (4.9–17.9) |
Total protein | |
 High, N(%) | 87 (32.2) |
 Low, N(%) | 6 (2.2) |
 Not available, N(%) | 177 (65.6) |
Mean corpuscular volume | |
 High, N(%) | 85 (31.5) |
 Normal, N(%) | 81 (30.0) |
 Low, N(%) | 5 (1.9) |
 Not available, N(%) | 99 (37.6) |
White blood cells count | |
 High, N(%) | 54 (20.0) |
 Normal, N(%) | 185 (68.5) |
 Low, N(%) | 7 (2.6) |
 Not available, N(%) | 24 (8.9) |